{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T01:28:35Z","timestamp":1747186115173,"version":"3.40.5"},"reference-count":127,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Evaluation Clinical Practice"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Rationale, aims, and objectives<\/jats:title><jats:p>One of the sectors challenged by the COVID\u201019 pandemic is medical research. COVID\u201019 originates from a novel coronavirus (SARS\u2010CoV\u20102) and the scientific community is faced with the daunting task of creating a novel model for this pandemic or, in other words, creating novel science. This paper is the first part of a series of two papers that explore the intricate relationship between the different challenges that have hindered biomedical research and the generation of scientific knowledge during the COVID\u201019 pandemic.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>During the early stages of the pandemic, research conducted on hydroxychloroquine (HCQ) was chaotic and sparked several heated debates with respect to the scientific methods used and the quality of knowledge generated. Research on HCQ is used as a case study in both papers. The authors explored biomedical databases, peer\u2010reviewed journals, pre\u2010print servers, and media articles to identify relevant literature on HCQ and COVID\u201019, and examined philosophical perspectives on medical research in the context of this pandemic and previous global health challenges.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>This paper demonstrates that a lack of prioritization among research questions and therapeutics was responsible for the duplication of clinical trials and the dispersion of precious resources. Study designs, aimed at minimising biases and increasing objectivity, were, instead, the subject of fruitless oppositions. The duplication of research works, combined with poor\u2010quality research, has greatly contributed to slowing down the creation of novel scientific knowledge.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The COVID\u201019 pandemic presented challenges in terms of (1) finding and prioritising relevant research questions and (2) choosing study designs that are appropriate for a time of emergency.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jep.13550","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T14:56:48Z","timestamp":1613660208000},"page":"694-707","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["<scp>COVID<\/scp>\u201019 and the generation of novel scientific knowledge: Research questions and study designs"],"prefix":"10.1111","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5124-8570","authenticated-orcid":false,"given":"Lucie","family":"Perillat","sequence":"first","affiliation":[{"name":"Faculty of Arts and Science University of Toronto Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian S.","family":"Baigrie","sequence":"additional","affiliation":[{"name":"Institute for the History and Philosophy of Science and Technology University of Toronto Toronto Ontario Canada"},{"name":"Institute of Health Policy, Management and Evaluation Dalla Lana School of Public Health, University of Toronto Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,2,15]]},"reference":[{"volume-title":"A Coordinated Global Research Roadmap: 2019 Novel Coronavirus","year":"2020","author":"World Health Organisation","key":"e_1_2_11_2_1"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1719902"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30251-8"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30129-8"},{"volume-title":"Guidance for Managing Ethical Issues in Infectious Disease Outbreaks","year":"2016","author":"WHO","key":"e_1_2_11_6_1"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsb1209510"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1717-y"},{"volume-title":"An R&D Blueprint for Action to Prevent Epidemics: Plan of Action","year":"2016","author":"WHO","key":"e_1_2_11_9_1"},{"issue":"1","key":"e_1_2_11_10_1","first-page":"22","article-title":"Role of adjunctive treatment strategies in COVID\u201019 and a review of international and national clinical guidelines","volume":"7","author":"Xu X","year":"2020","journal-title":"Mil Med Res"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4984"},{"key":"e_1_2_11_12_1","unstructured":"REMAP\u2010CAP.Pandemic preparedness\u2014REMAP\u2010CAP trial.https:\/\/www.remapcap.org\/pandemic-preparedness. Accessed January 16 2021."},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2589-7500(20)30082-0"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2020.305686"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1847"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60329-9"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.17226\/24739"},{"issue":"3","key":"e_1_2_11_18_1","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3201\/eid1003.030702","article-title":"Novel pathogens: lessons learned from SARS","volume":"10","author":"Muller MP","year":"2004","journal-title":"Emerg Infect Dis"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-virology-013120-013123"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/jep.13474"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-15-4"},{"key":"e_1_2_11_22_1","unstructured":"WHO.WHO R&D Blueprint: Informal consultation on prioritization of candidate therapeutic agents for use in novel coronavirus 2019 infection.https:\/\/extranet.who.int\/iris\/restricted\/handle\/10665\/330680.2020. Accessed December 19 2020."},{"volume-title":"WHO R&D Blueprint Novel Coronavirus: WHO Working Group\u2014Therapeutics Prioritization for COVID\u201019","year":"2020","author":"WHO","key":"e_1_2_11_23_1"},{"volume-title":"WHO R & D blueprint COVID\u201019 experimental treatments","year":"2020","author":"WHO","key":"e_1_2_11_24_1"},{"key":"e_1_2_11_25_1","unstructured":"WHO.COVID\u201019 Living Research Map.https:\/\/www.covid-nma.com\/dataviz\/.2020. Accessed January 16 2021."},{"key":"e_1_2_11_26_1","unstructured":"WHO.Ethical standards for research during public health emergencies: Distilling existing guidance to support COVID\u201019 R&D.https:\/\/apps.who.int\/iris\/handle\/10665\/331507.2020. Accessed December 19 2020."},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.090976"},{"key":"e_1_2_11_28_1","first-page":"796","volume-title":"The Oxford Handbook of Public Health Ethics","author":"Smith M","year":"2019"},{"key":"e_1_2_11_29_1","unstructured":"INSERM.La science pour la sant\u00e9. Covid\u201019: Essai Discovery point d'\u00e9tape au 7 mai 2020. science pour la sant\u00e9.2020.https:\/\/www.inserm.fr\/actualites\u2010et\u2010evenements\/actualites\/covid\u201019\u2010essai\u2010discovery\u2010point\u2010etape\u20107\u2010mai\u20102020. Accessed December 19 2020."},{"key":"e_1_2_11_30_1","unstructured":"SMART IRB.SMART IRB: National IRB Reliance Initiativehttps:\/\/smartirb.org\/. Accessed December 19 2020."},{"key":"e_1_2_11_31_1","unstructured":"NIH.Trial Innovation Network.https:\/\/ncats.nih.gov\/ctsa\/projects\/network.2018. Accessed December 19 2020."},{"key":"e_1_2_11_32_1","unstructured":"COVID\u201019 CP.COVID\u201019 collaboration platform.https:\/\/covidcp.org\/faq\/.2020. Accessed December 19 2020."},{"key":"e_1_2_11_33_1","article-title":"Ask an expert: why are there so many COVID\u201019 vaccines \u2013 and is it better to have more?","author":"Global Citizen","year":"2020","journal-title":"GAVI the Vaccine Alliance"},{"key":"e_1_2_11_34_1","unstructured":"UN News.UN health chief announces global \u201csolidarity trial\u201d to jumpstart search for COVID\u201019 treatment.https:\/\/news.un.org\/en\/story\/2020\/03\/1059722.2020. Accessed December 19 2020."},{"key":"e_1_2_11_35_1","unstructured":"UPMC.2020.Led global effort fast tracks testing of COVID\u201019 therapies.https:\/\/www.upmc.com\/media\/news\/040920-innovative-clinical-trials. Accessed December 19 2020."},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2020.04.016"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.7326\/M20-1223"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2020.1792778"},{"key":"e_1_2_11_39_1","unstructured":"WHO.Coronavirus disease (COVID\u201019): Hydroxychloroquine;2020.https:\/\/www.who.int\/news\u2010room\/q\u2010a\u2010detail\/coronavirus\u2010disease\u2010covid\u201019\u2010hydroxychloroquine. Accessed November 22 2020."},{"key":"e_1_2_11_40_1","unstructured":"FDA.Coronavirus (COVID\u201019) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine.https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/coronavirus\u2010covid\u201019\u2010update\u2010fda\u2010revokes\u2010emergency\u2010use\u2010authorization\u2010chloroquine\u2010and.2020. Accessed November 22 2020."},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.5582\/bst.2020.01047"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-020-09930-x"},{"key":"e_1_2_11_43_1","doi-asserted-by":"crossref","unstructured":"SuranagiUD RehanHS GoyalN.Review of current evidence of hydroxychloroquine in pharmacotherapy of COVID\u201019. medRxiv; 2020. doi:https:\/\/doi.org\/10.1101\/2020.04.16.20068205.","DOI":"10.1101\/2020.04.16.20068205"},{"key":"e_1_2_11_44_1","first-page":"1","volume-title":"Targeted update: safety and efficacy of hydroxychloroquine or chloroquine for treatment of COVID\u201019","author":"Cochrane Response","year":"2020"},{"key":"e_1_2_11_45_1","unstructured":"H\u00f4pitaux Universitaires de Gen\u00e8ve D\u00e9partement de M\u00e9decine Aig\u00fce.Chloroquine hydroxychloroquine et COVID\u201019: \u00e9valuation pharmacologique.https:\/\/www.hug.ch\/sites\/interhug\/files\/structures\/coronavirus\/documents\/hydroxy\u2010chloroquine\u2010et\u2010covid\u201019.pdf.2020. Accessed December 19 2020."},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/acem.14005"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2020.1839959"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105949"},{"key":"e_1_2_11_49_1","unstructured":"ChenZ HuJ ZhangZ et al.Efficacy of hydroxychloroquine in patients with COVID\u201019: results of a randomized clinical trial. medRxiv; 2020;7. doi:https:\/\/doi.org\/10.1101\/.20040758"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2020.101663"},{"key":"e_1_2_11_51_1","doi-asserted-by":"crossref","unstructured":"DavidoB LansamanT BessisS et al.Hydroxychloroquine plus azithromycin: a potential interest in reducing in\u2010hospital morbidity due to COVID\u201019 pneumonia (HI\u2010ZY\u2010COVID)? medRxiv; 2020. doi:https:\/\/doi.org\/10.1101\/2020.05.05.20088757.","DOI":"10.1101\/2020.05.05.20088757"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/nsr\/nwaa113"},{"key":"e_1_2_11_53_1","doi-asserted-by":"crossref","unstructured":"AhmadI AlamM SaadiR MahmudS SaadiE.Doxycycline and hydroxychloroquine as treatment for high\u2010riskCOVID\u201019 patients: experience from case series of 54 patients in long\u2010term care facilities. medRxiv; 2020.https:\/\/doi.org\/10.1101\/2020.05.18.20066902.","DOI":"10.1101\/2020.05.18.20066902"},{"key":"e_1_2_11_54_1","doi-asserted-by":"crossref","unstructured":"YuB WangDW LiC.Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID\u201019. medRxiv; 2020. doi:https:\/\/doi.org\/10.1101\/2020.04.27.20073379","DOI":"10.1101\/2020.04.27.20073379"},{"key":"e_1_2_11_55_1","doi-asserted-by":"crossref","unstructured":"deNovalesF et al.Early hydroxychloroquine is associated with anincrease of survival in COVID\u201019 patients: an obser\u2010vational study. Preprints; 2020:1\u201337. doi:https:\/\/doi.org\/10.20944\/preprints202005.0057.v1","DOI":"10.20944\/preprints202005.0057.v1"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2020.101738"},{"key":"e_1_2_11_57_1","doi-asserted-by":"crossref","unstructured":"KimMS JangS\u2010W ParkY\u2010K et al.Treatment response to hydroxychloroquine lopinavir\/ritonavir and antibiotics for moderate COVID 19: A first report on the pharmacological outcomes from South Korea; 2020. doi:https:\/\/doi.org\/10.1101\/2020.05.13.20094193","DOI":"10.1101\/2020.05.13.20094193"},{"key":"e_1_2_11_58_1","unstructured":"ChenL ZhangZ FuJ et al.Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID\u201019: a prospective open\u2010label randomized controlled study; 2020. doi:https:\/\/doi.org\/10.1101\/.20136093."},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.06.099"},{"issue":"2","key":"e_1_2_11_60_1","first-page":"215","article-title":"A pilot study of hydroxychloroquine in treatment of patients with moderate COVID\u201019","volume":"49","author":"Chen J","year":"2020","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medmal.2020.03.006"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2020.06.001"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012410"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.8630"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1849"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1844"},{"key":"e_1_2_11_67_1","doi-asserted-by":"crossref","unstructured":"SinghS KhanA ChowdhryM et al.Outcomes of hydroxychloroquine treatment among hospitalized COVID\u201019 patients in the United States\u2010 real\u2010world evidence from a we acknowledge the West Virginia Clinical and translational science institute to provide us access and training to the TriNETX. medRxiv; 2020. doi:https:\/\/doi.org\/10.1101\/2020.05.12.20099028.","DOI":"10.1101\/2020.05.12.20099028"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0237693"},{"key":"e_1_2_11_69_1","first-page":"1","article-title":"Compassionate use of hydroxychloroquine in clinicalpractice for patients with mild to severe COVID\u201019 ina French university hospital","author":"Paccoud O","year":"2020","journal-title":"Clin Infect Dis"},{"key":"e_1_2_11_70_1","doi-asserted-by":"crossref","unstructured":"Faico\u2010FilhoKS ConteDD Souza LunaLK CarvalhoJMA PerosaAHS BelleiN.Effect of hydroxychloroquine on SARS\u2010CoV\u20102 viral load in patients with COVID\u201019; 2020. doi:https:\/\/doi.org\/10.1101\/2020.06.16.20133066","DOI":"10.1101\/2020.06.16.20133066"},{"key":"e_1_2_11_71_1","doi-asserted-by":"crossref","unstructured":"SbidianEet al.Hydroxychloroquinewith or without azithromycin and in\u2010hospital mortalityor discharge in patients hospitalized for COVID\u201019 infec\u2010tion: a cohort study of 4 642 in\u2010patients in France. medRxiv; 2020:1\u201323. doi:https:\/\/doi.org\/10.1101\/2020.06.16.20132597.","DOI":"10.1101\/2020.06.16.20132597"},{"key":"e_1_2_11_72_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-03117-9"},{"key":"e_1_2_11_73_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022926"},{"key":"e_1_2_11_74_1","first-page":"1","article-title":"Hydroxychloroquine for early treatment of adults with mild Covid\u201019: a randomized\u2010controlled trial","author":"Mitj\u00e0 O","year":"2020","journal-title":"Clin Infect Dis"},{"key":"e_1_2_11_75_1","first-page":"1","article-title":"A multicenter, randomized, open\u2010label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate Coronavirus disease 2019 (COVID\u201019)","volume":"2019","author":"Chen C\u2010P","year":"2020","journal-title":"PLos One"},{"key":"e_1_2_11_76_1","doi-asserted-by":"publisher","DOI":"10.7326\/M20-4207"},{"key":"e_1_2_11_77_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.8857"},{"key":"e_1_2_11_78_1","first-page":"1","article-title":"Clinical outcomes of hydroxychloroquine in hospitalized patients with COVID\u201019: a quasi\u2010randomized comparative study","author":"Barbosa J","year":"2020","journal-title":"NEJM"},{"issue":"20","key":"e_1_2_11_79_1","first-page":"1","article-title":"RETRACTED: hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID\u201019: a multinational registry analysis","volume":"6736","author":"Mehra MR","year":"2020","journal-title":"Lancet"},{"key":"e_1_2_11_80_1","doi-asserted-by":"crossref","unstructured":"MallatJ HamedF BalkisM et al.Hydroxychloroquine is associated with slower viral clearance in clinical COVID\u201019 patients with mild to moderate disease: A retrospective study.2020:1\u201321.doi:10.1101\/2020.04.27.20082180","DOI":"10.1101\/2020.04.27.20082180"},{"issue":"20","key":"e_1_2_11_81_1","first-page":"1016","article-title":"Chloroquine or hydroxychloroquine for COVID\u201019: why might they be hazardous?","volume":"6736","author":"Funck\u2010Brentano C","year":"2020","journal-title":"Lancet"},{"key":"e_1_2_11_82_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc1731"},{"key":"e_1_2_11_83_1","article-title":"On ne peut pas d\u00e9cider de l'utilit\u00e9 d'un traitement sur une intuition","author":"Meyer N","year":"2020","journal-title":"Le Monde"},{"key":"e_1_2_11_84_1","unstructured":"TrumpD.https:\/\/twitter.com\/realdonaldtrump\/status\/1241367239900778501. Accessed November 22 20202020"},{"key":"e_1_2_11_85_1","unstructured":"RaoultD.Le m\u00e9decin peut et doit r\u00e9fl\u00e9chir comme un m\u00e9decin et non pas comme un m\u00e9thodologiste;2020.https:\/\/www.lemonde.fr\/idees\/article\/2020\/03\/25\/didier\u2010raoult\u2010le\u2010medecin\u2010peut\u2010et\u2010doit\u2010reflechir\u2010comme\u2010un\u2010medecin\u2010et\u2010non\u2010pas\u2010comme\u2010un\u2010methodologiste_6034436_3232.html. Accessed November 22 2020."},{"key":"e_1_2_11_86_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7429.1459"},{"key":"e_1_2_11_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61734-7"},{"key":"e_1_2_11_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2012.04.017"},{"key":"e_1_2_11_89_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.9.1021"},{"volume-title":"Adults Ambivalent about the Risks and Benefits of off\u2010Label Prescription Drug Use","year":"2006","author":"Cummings J","key":"e_1_2_11_90_1"},{"issue":"15","key":"e_1_2_11_91_1","first-page":"1448","article-title":"Treating COVID\u201019 off\u2010label drug use, compassionate use and randomized Clinical Trials during pandemics","volume":"375","author":"Kalil AC","year":"2020","journal-title":"JAMA"},{"key":"e_1_2_11_92_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI139562"},{"key":"e_1_2_11_93_1","unstructured":"RECOVERY.Statistical Analysis Plan RECOVERY; 2020.https:\/\/www.recoverytrial.net\/files\/recovery\u2010sap\u2010v1\u20100\u201009_06_20.pdf. Accessed November 22 2020."},{"key":"e_1_2_11_94_1","unstructured":"RECOVERY.Definition and derivation of baseline characteristics and outcomes; 2020.https:\/\/www.recoverytrial.net\/files\/recovery-outcomes-definitions-v1-0.pdf. Accessed November 22 2020."},{"key":"e_1_2_11_95_1","unstructured":"RECOVERY.Randomised evaluation of Covid\u201019 therapy (recovery); 2020.https:\/\/www.recoverytrial.net\/files\/recovery-protocol-v10-1-2020-11-01.pdf. Accessed November 22 2020."},{"key":"e_1_2_11_96_1","unstructured":"RECOVERY.Statement from the Chief Investigators of the RECOVERY Trial on hydroxychloroquine; June 5 2020.https:\/\/www.recoverytrial.net\/files\/hcq\u2010recovery\u2010statement\u2010050620\u2010final\u2010002.pdf. Accessed November 22 2020."},{"key":"e_1_2_11_97_1","unstructured":"FDA.Hydroxychloroquine fact sheet for health care providers; 2020.https:\/\/www.fda.gov\/media\/136538\/download. Accessed November 22 2020."},{"key":"e_1_2_11_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2020.03.012"},{"key":"e_1_2_11_99_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.7762"},{"key":"e_1_2_11_100_1","unstructured":"LovelaceB Feuer W.World Health Organization resumes coronavirus trial on malaria drug hydroxychloroquine after examining safety concerns; 2020.https:\/\/www.cnbc.com\/2020\/06\/03\/world\u2010health\u2010organization\u2010resumes\u2010coronavirus\u2010trial\u2010on\u2010malaria\u2010drug\u2010hydroxychloroquine\u2010after\u2010safety\u2010concerns.html. Accessed November 22 2020."},{"key":"e_1_2_11_101_1","unstructured":"Ministre de la Sant\u00e9 et des Solidarit\u00e9s.Avis du Haut Conseil \u00e0 la Sant\u00e9 Publique relatif \u00e0 l'utilisation de l'hydroxycholoroquine dans le Covid\u201019; 2020.https:\/\/www.google.com\/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwj19a3TjprtAhVyFFkFHbIVCx8QFjABegQIAxAC&url=https%3A%2F%2Fwww.hcsp.fr%2FExplore.cgi%2FTelecharger%3FNomFichier%3Dhcspa20200524_covidutilidelhydro.pdf&usg=AOvVaw1xB96b0EfNosvBX5iIIWPV. Accessed November 22 2020."},{"key":"e_1_2_11_102_1","unstructured":"WatsonJ. A(Longish) post\u2010publication review of the most recent observational study in COVID19 patients treated with (hydroxy)chloroquine. This is retrospective analysis of an international registry with 96 000 hospitalised patients in 6 continents; 2020.https:\/\/twitter.com\/jwato_watson\/status\/1264793409618935809. Accessed November 22 2020."},{"key":"e_1_2_11_103_1","unstructured":"WastonJ Al.E.Open letter to MR Mehra SS Desai F Ruschitzka and AN Patel and to Richard Horton (editor of The Lancet); 2020.https:\/\/zenodo.org\/record\/3862789#.X7x1SVnCpI0. Accessed November 22 2020."},{"key":"e_1_2_11_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31324-6"},{"key":"e_1_2_11_105_1","unstructured":"BratGA WeberGM GehlenborgN et al.International Electronic Health Record\u2010Derived COVID\u201019 Clinical Course Profile: The 4CE Consortium; 2020. doi:https:\/\/doi.org\/10.1101\/.20059691."},{"key":"e_1_2_11_106_1","unstructured":"4CE.Consortium for clinical characterization of COVID\u201019 by EHR; 2020.https:\/\/covidclinical.net\/. Accessed November 22 2020."},{"key":"e_1_2_11_107_1","first-page":"1","article-title":"Anonymising and sharing individual patient data","volume":"350","author":"El EK","year":"2015","journal-title":"BMJ"},{"key":"e_1_2_11_108_1","unstructured":"AbramowitzS.Data sharing in public health emergencies: Anthropological and historical perspectives on data sharing during the 2014\u20132016 Ebola epidemic and the 2016 yellow fever epidemic; 2018:124."},{"key":"e_1_2_11_109_1","unstructured":"WHO.WHO consultation on data and results sharing during public health emergencies. Background briefing; 2015.http:\/\/www.who.int\/medicines\/ebola\u2010treatment\/background_briefing_on_data_results_sharing_during_phes.pdf. Accessed November 22 2020."},{"key":"e_1_2_11_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2589-7500(20)30132-1"},{"key":"e_1_2_11_111_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsb1905390"},{"key":"e_1_2_11_112_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.5775"},{"key":"e_1_2_11_113_1","unstructured":"REMAP\u2010CAP.REMAP\u2010CAP randomized embedded multifactorial adaptive platform trial for community\u2010acquired pneumonia (REMAP\u2010CAP): Pandemic appendix to the core protocol; 2020.https:\/\/static1.squarespace.com\/static\/5cde3c7d9a69340001d79ffe\/t\/5f1bb6657fbac53ab4d79938\/1595651697549\/REMAP-CAP+-+PAtC+-+V2.0+-+18+May+2020_WM.pdf. Accessed November 22 2020."},{"key":"e_1_2_11_114_1","unstructured":"CAPTIC.The REMAP\u2010CAP trial; 2020.https:\/\/www.captic.ca\/the-remap-cap-trial. Accessed November 22 2020."},{"key":"e_1_2_11_115_1","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.202003-192SD"},{"key":"e_1_2_11_116_1","unstructured":"REMAP\u2010CAP.REMAP\u2010CAP: Core protocol; 2019.https:\/\/static1.squarespace.com\/static\/5cde3c7d9a69340001d79ffe\/t\/5e82b62eda9c1c714065efc0\/1585624649154\/REMAP\u2010CAP+Core+Protocol+V3+\u2010+10+July+2019_WM.pdf. Accessed November 22 2020."},{"key":"e_1_2_11_117_1","unstructured":"REMAP\u2010CAP.Domain\u2010specific appendix: COVID\u201019 Antiviral therapy; 2020.https:\/\/static1.squarespace.com\/static\/5cde3c7d9a69340001d79ffe\/t\/5ea3fd83f222897b8d528195\/1587805583231\/REMAP\u2010CAP+\u2010+COVID\u201019+Antiviral+Domain\u2010Specific+Appendix+V2.0+\u2010+01+April+2020_WM.pdf. Accessed November 22 2020."},{"key":"e_1_2_11_118_1","unstructured":"REMAP\u2010CAP.REMAP\u2010CAP appendix to core protocol: statistical analysis appendix; 2019.https:\/\/static1.squarespace.com\/static\/5cde3c7d9a69340001d79ffe\/t\/5e82b68a143343364b38c10c\/1585624721568\/REMAP\u2010CAP+Statistical+Analysis+Appendix+V3+\u2010+24+August+2019_WM.pdf. Accessed November 22 2020."},{"key":"e_1_2_11_119_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0034-3"},{"volume-title":"Adaptive Designs for Clinical Trials of Drugs and Biologics FDA Guidance for Industry","year":"2019","author":"U.S. Department of Health and Human Services Food and Drug Administration","key":"e_1_2_11_120_1"},{"key":"e_1_2_11_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2017.09.002"},{"key":"e_1_2_11_122_1","doi-asserted-by":"publisher","DOI":"10.1177\/1740774514563583"},{"key":"e_1_2_11_123_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs404"},{"key":"e_1_2_11_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2020.04.019"},{"key":"e_1_2_11_125_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0760-x"},{"key":"e_1_2_11_126_1","unstructured":"HorbyP.RECOVERY trial\u2014Randomised evaluation of COVID\u201019 therapy; 2020.https:\/\/www.recoverytrial.net\/. Accessed November 22 2020."},{"key":"e_1_2_11_127_1","doi-asserted-by":"crossref","unstructured":"AngusDC DerdeL Al\u2010BeidhF et al.Effect of hydrocortisone on mortality and organ support in patients with severe COVID\u201019: The REMAP\u2010CAP COVID\u201019 corticosteroid domain randomized clinical trial.2020;324(13):1317\u20131329.doi:https:\/\/doi.org\/10.1001\/jama.2020.17022","DOI":"10.1001\/jama.2020.17022"},{"key":"e_1_2_11_128_1","unstructured":"REMAP\u2010CAPHydroxychloroquine; n.d..https:\/\/www.lifespan.io\/road-maps\/the-covid-19-roadmap\/remap-cap-hydroxychloroquine. Accessed November 22 2020"}],"container-title":["Journal of Evaluation in Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jep.13550","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jep.13550","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jep.13550","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T11:53:11Z","timestamp":1724500391000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jep.13550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,15]]},"references-count":127,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1111\/jep.13550"],"URL":"https:\/\/doi.org\/10.1111\/jep.13550","archive":["Portico"],"relation":{},"ISSN":["1356-1294","1365-2753"],"issn-type":[{"type":"print","value":"1356-1294"},{"type":"electronic","value":"1365-2753"}],"subject":[],"published":{"date-parts":[[2021,2,15]]},"assertion":[{"value":"2020-12-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}